Biomarin Pharmaceutical Inc., of San Rafael, Calif., entered a settlement agreement with Par Pharmaceutical Inc., of Woodcliff Lake, N.J., that resolves patent litigation in the U.S. related to Biomarin's phenylketonuria therapy, Kuvan (sapropterin dihydrochloride) 100 mg oral tablets and powder for oral solution in 100 mg packets. Under the terms of the settlement, Biomarin will grant Par a nonexclusive license to its patents related to Kuvan to allow Par to market a generic version of sapropterin dihydrochloride in the U.S. for the indications approved for Kuvan beginning Oct. 1, 2020, or earlier under certain circumstances. Other details of the agreement remain confidential.